Table 2. Landmark analyses performed at 6, 9 and 12 months to determine the impact of lenalidomide dose on PFS.
|
Median PFS, months (95% CI) |
|||
|---|---|---|---|
| Dose reduction at or after time point | Dose reduction before time point | No dose reduction | |
| 6 months | n=50 | n=40 | n=79 |
| 28.6 (20.5–46.9) | 24.7 (16.6–36.7) | 19.8 (25.1–29.0) | |
| P=0.388 | P=0.069 | ||
| 9 months | n=39 | n=37 | n=63 |
| 44.4 (21.9–NR) | 24.7 (17.0–36.7) | 26.2 (19.7–39.6) | |
| P=0.256 | P=0.128 | ||
| 12 months | n=25 | n=39 | n=52 |
| NR (35.7–NR) | 28.0 (17.5–36.7) | 36.8 (22.1–NR) | |
| P=0.007 | P=0.039 | ||
Abbreviations: CI, confidence interval; NR, not reached; PFS, progression-free survival.
P-values are vs dose reduction after time point (log-rank test).